Clinical lung cancer
-
Clinical lung cancer · Sep 2009
ReviewQuality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer.
Non-small-cell lung cancer (NSCLC) care is multidisciplinary and complex in nature. However, there are few quality indicators that are widely accepted by the physicians who treat lung cancer. ⋯ In this article we review the current state of quality indicators in oncology care in general and for NSCLC in particular. Proposed quality metrics focus on diagnosis and staging, timeliness of care, supportive care and patient satisfaction.
-
Clinical lung cancer · Sep 2009
Comparative StudyComputed tomography-guided percutaneous needle biopsy of pulmonary nodules: impact of nodule size on diagnostic accuracy.
This study was undertaken to compare the diagnostic accuracy and complication rate of computed tomography (CT)-guided percutaneous lung biopsies of lung nodules
-
Clinical lung cancer · Sep 2009
Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
The survival rates for stage IIIA and stage IIIB non-small-cell lung cancer (NSCLC) are extremely poor with single-treatment modalities such as radiation therapy or surgery. The purpose of this study is to assess tolerability, response, surgical resectability, and survival of chemotherapy followed by chemoradiation therapy, and then followed by surgery in patients with stage IIIA (N2-bulky) or stage IIIB NSCLC. ⋯ Preoperative sequence of chemotherapy followed by concurrent chemoradiation therapy is an effective approach in patients with stage IIIA (N2-bulky) and IIIB (T4 N1-2 M0) NSCLC. The operation after induction chemoradiation therapy should be performed in carefully selected patients with surgically resectable diseases. The patients who achieved complete resection and with pathologic response of tumor can benefit from surgery following induction chemoradiation therapy.